Jiajian Xiaohuang Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a standardized multi-component botanical powder rather than a crude milled herb. The grade is differentiated by model code: JXH-VET-API-01 is intended for non-sterile solid oral forms, while JXH-VET-API-02 is the low-endotoxin fraction developed for solutions and injectable preparations. The distinction rests on particle-size control, bioburden, and bacterial endotoxin burden, not on a change in active-marker identity. Since no harmonized international monograph exists under this trade name, the certificate of analysis is aligned with the receiving manufacturer’s dossier and pharmacopoeial general chapters, including USP <561> for articles of botanical origin.

For tableting and encapsulation, the powder is specified with a laser-diffraction particle size D90 ≤ 150 µm and a Hausner ratio below 1.35 to maintain die-fill consistency on rotary presses. Loss on drying is controlled under USP <731>; residual moisture is typically held below 5.0% to reduce sticking, capping, and punch filming. Direct compression is feasible only when the material is pre-conditioned below 60% relative humidity; above that threshold, a fluid-bed dryer or tray dryer operating at 50–60°C inlet air is used before compression. Tablet hardness is monitored under USP <1217>, and friability is assessed under USP <1216> with a limit of not more than 1.0% for uncoated cores.

Wet granulation is selected when the drug load exceeds 30% w/w of the core mass or when direct compression produces unacceptable segregation. A high-shear granulator with impeller and chopper controls is used; binder solution is added at 2–5% w/w, and the end point is determined by power draw and impeller torque rather than fixed time. Granules are dried to residual moisture of not more than 3.0% before addition of disintegrant and lubricant. The dried granules are milled through a 1.0 mm screen, and the 20–80 mesh fraction is collected for compression. Published data for this specific configuration is limited; therefore, process windows should be verified with site-specific formulation studies.

The specification framework commonly applied to this ingredient class is summarized below. The values are representative pharmacopoeial control ranges for botanical APIs, not batch-specific release results for this trade-name product.

What Limits Injectable Clarity and Endotoxin Acceptance in a Multi-Component Veterinary API?

For injectable solutions, the critical quality attributes shift from flow and compressibility to reconstitution clarity, pH stability, particulate burden, and pyrogen control. The JXH-VET-API-02 grade is prepared with a smaller particle size and tested for bacterial endotoxins under USP <85>. Because endotoxin limits are dose- and species-dependent, a universal acceptance value cannot be assigned; the limit is calculated from the maximum intended dose and the target species. Solutions are clarified through 0.45 µm pre-filtration and sterilized through 0.22 µm membrane filters, with light obscuration testing under USP <788> for particles ≥ 10 µm and ≥ 25 µm. The solution pH is typically adjusted to 7.0–7.6 for intravenous administration unless stability data support an alternative range.

Although no incompatibility dataset for this specific product has been published, botanical materials containing polyphenolic constituents often show reduced clarity when formulated with iron or aluminum salts and may exhibit pH-dependent precipitation with phosphate buffers. Therefore, excipient compatibility screening should include visual inspection at 0, 24, and 48 h at 25 ± 2°C and 2–8°C, and filterability should be measured as volume throughput per 0.22 µm membrane before committing to a parenteral formulation. Terminal sterilization by autoclaving may alter marker content if pH is outside 4.0–7.0; aseptic filtration is therefore preferred for heat-sensitive batches.

During encapsulation, the powder is blended with colloidal silicon dioxide at 0.5–1.0% w/w and magnesium stearate at 0.25–1.0% w/w. Tamping-pin capsule fillers require adjustment of compression ratio when poured bulk density falls below 0.45 g/mL; otherwise, weight variation may fail the acceptance criteria described in USP <905>. In oral powder and granule packaging, the bulk material is filled by volumetric auger equipment. Fill weight is monitored at 10–15 minute intervals, and moisture content is re-checked after 4 h exposure to ambient air to detect hygroscopic drift.

In premix production, the API is first geometrically diluted with lactose monohydrate or dextrose at a ratio of 1:5 to 1:10 before addition to a ribbon blender or paddle mixer. Mix uniformity is tested at 10 sampling points with an acceptance range of 90.0–110.0% of labeled marker content and relative standard deviation not more than 5.0%. Total mixing time is typically 15–20 minutes in a 200–500 kg ribbon blender, but the value should be re-established after any change in bulk density or particle size. Dusting and segregation are reduced by adding 0.5–1.0% vegetable oil or mineral oil; this also lowers electrostatic adhesion to stainless-steel surfaces.

When This Powder Replaces a Crude Milled Herb in a Registered Premix

Substitution of a crude milled herb with the veterinary-grade API changes more than assay content. Crude herbal powders may carry total aerobic microbial counts above 10⁴ CFU/g, particle sizes above 250 µm, and variable marker distribution; the veterinary-grade material is tested under USP <61> and USP <62> for batch release. In a fixed-mixing-time premix line, the shift to a finer standardized powder decreases assay variability but can increase dust generation and electrostatic adhesion to stainless-steel surfaces. The use of a pre-blend step at 10–15 minutes and a main blend at 15–20 minutes is usually adequate when the API has a poured bulk density above 0.40 g/mL. However, published data for this specific product is limited, so blend uniformity should be re-qualified at site-specific humidity and ribbon speed conditions.

Compared with single-entity synthetic veterinary APIs, this powder requires chromatographic fingerprinting rather than a single-peak purity assay. High-performance liquid chromatography with photodiode-array detection is used to monitor marker retention times and relative peak areas; a similarity index above 0.95 against the reference chromatogram is commonly applied in raw-material acceptance. Residual solvent analysis under USP <467> verifies that Class 2 solvents remain below their permitted daily exposure limits. Elemental impurities are assessed using USP <233>; acceptance limits are derived from the finished dosage form’s maximum daily dose and route according to USP <232>.

Particle-size reduction is performed with a jet mill or pin mill under nitrogen sweep for heat-sensitive batches. For the injectable grade, a spiral jet mill with classifier setting corresponding to D90 ≤ 50 µm is used; the feed rate is adjusted to maintain mill outlet temperature below 40°C. The micronized powder is then vacuum-dried at 40–45°C for 8–12 h before endotoxin and bioburden sampling. This step is critical because over-milling can increase surface energy and electrostatic charge, leading to poor flow even when particle size complies with the specification.

The active-marker content is determined by high-performance liquid chromatography with a method validated for specificity, linearity over 50–150% of the target concentration, and precision with relative standard deviation not more than 2.0% for system suitability. Loss on drying is measured by USP <731>, and moisture is also confirmed by Karl Fischer titration under USP <921> when bound water is suspected. Heavy metals are screened by inductively coupled plasma mass spectrometry under USP <233>; the absence of an established monograph means that acceptance limits are set by the finished product’s maximum daily dose and species-specific toxicological data.

Stability samples are stored in double polyethylene bags inside fiber drums at 25 ± 2°C / 60 ± 5% RH and 40 ± 2°C / 75 ± 5% RH according to ICH Q1A(R2). The powder should not be stored in unlined metal containers because tannins and polyphenolic acids can react with iron and aluminum; stainless steel 316L or glass contact surfaces are preferred. A retest period of 24 months is typical for botanical extracts when initial and accelerated stability data support it, but site-specific hold-time studies remain mandatory for this product because no published long-term stability monograph exists.

A known scale-up failure mode in direct compression of botanical extracts is extreme elastic recovery after ejection. When tablet cores show capping at hardness above 10 kp, the formulation is moved to wet granulation or roller compaction. Roller compaction is performed at a hydraulic pressure of 20–80 bar; the ribbon is milled through a 1.0 mm screen, and fines below 10% of total granule mass are controlled to avoid segregation. This problem is more pronounced at API loadings above 50% w/w and at ambient humidity below 20%, where static charging increases.

The manufacturing site should operate under veterinary active pharmaceutical ingredient good manufacturing practice, typically aligned with EU GMP Part II or equivalent national regulations. Documentation includes a drug master file, certified batch records, and a certificate of analysis. Residual solvent limits are assigned under VICH GL18 and USP <467>; mutagenic impurities are assessed under ICH M7 when applicable. The product does not claim sterility in its API form, so downstream sterile filtration or terminal sterilization is required for injectable dosage forms.

For oral solutions, the powder is dispersed in purified water or a buffered vehicle and pH is adjusted to 4.0–6.5 to improve palatability and stability for swine and poultry. The solution may be used within 24–48 h after reconstitution when stored at 2–8°C, but in-use stability should be confirmed by marker assay at the site of use. For injection, a clear solution after prefiltration is mandatory; any visible turbidity, color shift beyond the established range, or pH drift above 0.3 units indicates batch failure. The API is not supplied sterile; sterilization is performed at the finished-product manufacturing stage by aseptic filtration or terminal heat treatment.